Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection

[1]  David Atkins,et al.  AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program. , 2010, Journal of clinical epidemiology.

[2]  David Moher,et al.  AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. , 2010, Journal of clinical epidemiology.

[3]  Howard Balshem,et al.  AHRQ series paper 2: principles for developing guidance: AHRQ and the effective health-care program. , 2010, Journal of clinical epidemiology.

[4]  Byron C. Wallace,et al.  Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data , 2009, BMC medical research methodology.

[5]  G. Dusheiko.  Cost-effectiveness of oral treatments for chronic hepatitis B. , 2009, Journal of hepatology.

[6]  M. Buti,et al.  Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. , 2009, Journal of hepatology.

[7]  S. Greenfield,et al.  Comparative Effectiveness Research: A Report From the Institute of Medicine , 2009, Annals of Internal Medicine.

[8]  J. Reichen.  Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B , 2009, Annals of Internal Medicine.

[9]  J. Feld,et al.  Endpoints of therapy in chronic hepatitis B , 2009, Hepatology.

[10]  I. Gareen,et al.  National Institutes of Health consensus development conference statement: Management of hepatitis B , 2009, Hepatology.

[11]  M. Ghany,et al.  Antiviral resistance and hepatitis B therapy , 2009, Hepatology.

[12]  J. Dienstag.  Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.

[13]  T. Wilt,et al.  Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence , 2009, Hepatology.

[14]  R. Fontana.  Side effects of long‐term oral antiviral therapy for hepatitis B , 2009, Hepatology.

[15]  R. Perrillo.  Benefits and risks of interferon therapy for hepatitis B , 2009, Hepatology.

[16]  Chien-Jen Chen,et al.  Hepatitis B virus DNA levels and outcomes in chronic hepatitis B , 2009, Hepatology.

[17]  T. Wilt,et al.  Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference , 2009, Annals of Internal Medicine.

[18]  F. Lu,et al.  Management of hepatitis B in China. , 2009, Chinese medical journal.

[19]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[20]  T. Wilt,et al.  Management of chronic hepatitis B. , 2008, Evidence report/technology assessment.

[21]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[22]  J. Niu,et al.  Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double‐blind trial , 2007, Hepatology.

[23]  P. Marcellin,et al.  Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. , 2007, Annals of internal medicine.

[24]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[25]  W. Kim,et al.  Natural history of hepatitis B virus infection: an update for clinicians. , 2007, Mayo Clinic proceedings.

[26]  M. Buti,et al.  Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis , 2007, Hepatology.

[27]  Xinyue Chen,et al.  Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. , 2007, World journal of gastroenterology.

[28]  F. Roudot-thoraval,et al.  Guidelines for the diagnosis of uncomplicated cirrhosis. , 2007, Gastroenterologie clinique et biologique.

[29]  T. Karakan,et al.  Hepatic Steatosis has no Impact on the Outcome of Treatment in Patients With Chronic Hepatitis B Infection , 2007, Journal of clinical gastroenterology.

[30]  U. Akarca,et al.  Adefovir Dipivoxil Alone or in Combination with Lamivudine for Three Months in Patients with Lamivudine Resistant Compensated Chronic Hepatitis B , 2007, Digestive Diseases and Sciences.

[31]  M. Mizokami,et al.  Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Wolfgang Viechtbauer,et al.  Confidence intervals for the amount of heterogeneity in meta‐analysis , 2007, Statistics in medicine.

[33]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[34]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[35]  Liji Jin,et al.  Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. , 2006, The Journal of antimicrobial chemotherapy.

[36]  H. Janssen,et al.  Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine , 2006, The American Journal of Gastroenterology.

[37]  S. Zeuzem,et al.  Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response , 2006, Hepatology.

[38]  E. Palumbo,et al.  Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant. , 2006, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[39]  J. Shepherd,et al.  Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. , 2006, Health technology assessment.

[40]  Yue Chen,et al.  Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. , 2006, World journal of gastroenterology.

[41]  Hao Wang,et al.  A double‐blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg‐positive chronic hepatitis B , 2006, Hepatology.

[42]  V. Wong,et al.  Genetic polymorphisms of interleukin‐1‐beta in association with sustained response to anti‐viral treatment in chronic hepatitis B in Chinese , 2006, Alimentary pharmacology & therapeutics.

[43]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[44]  Jung-Hwan Yoon,et al.  High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study , 2006, Journal of Gastroenterology.

[45]  R. D. de Man,et al.  Peg‐interferon improves liver histology in patients with HBeAg‐positive chronic hepatitis B: no additional benefit of combination with lamivudine , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[46]  Hao Wang,et al.  Two-year Lamivudine treatment for Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial , 2006, Antiviral therapy.

[47]  Guido Knapp,et al.  Assessing the Amount of Heterogeneity in Random‐Effects Meta‐Analysis , 2006, Biometrical journal. Biometrische Zeitschrift.

[48]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[49]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[50]  H. Janssen,et al.  Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.

[51]  B. Sharma,et al.  Higher Efficacy of Sequential Therapy with Interferon-α and Lamivudine Combination Compared to Lamivudine Monotherapy in HBeAg Positive Chronic Hepatitis B Patients , 2005, The American Journal of Gastroenterology.

[52]  T. Trikalinos,et al.  Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B , 2005 .

[53]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[54]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[55]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[56]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[57]  V. Wong,et al.  Long‐term follow‐up of peginterferon and lamivudine combination treatment in HBeAg‐positive chronic hepatitis B , 2005, Hepatology.

[58]  R. D. de Man,et al.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.

[59]  G. Gerken,et al.  The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation , 2005, Alimentary pharmacology & therapeutics.

[60]  M. Yuen,et al.  Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy , 2005, Alimentary pharmacology & therapeutics.

[61]  Gordon H Guyatt,et al.  Systems for grading the quality of evidence and the strength of recommendations II: Pilot study of a new system , 2005, BMC health services research.

[62]  V. Wong,et al.  A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.

[63]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[64]  G. Guyatt,et al.  Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group , 2004, BMC health services research.

[65]  H. Lee,et al.  Combination of α‐interferon with lamivudine reduces viral breakthrough during long‐term therapy , 2004 .

[66]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[67]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[68]  J. Hulot,et al.  Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. , 2004, Kidney international.

[69]  M. Daikoku,et al.  [Lamivudine therapy for chronic hepatitis B]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[70]  Iain Chalmers,et al.  Well informed uncertainties about the effects of treatments , 2004, BMJ : British Medical Journal.

[71]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[72]  M. Wulfsohn,et al.  Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B , 2003, Hepatology.

[73]  C. Gibbs,et al.  Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil , 2003 .

[74]  Y. Çelik,et al.  Comparison of 12-Month Courses of Interferon-α-2b–Lamivudine Combination Therapy and Interferon-α-2b Monotherapy among Patients with Untreated Chronic Hepatitis B , 2003 .

[75]  E. Schiff,et al.  Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. , 2003, Journal of hepatology.

[76]  H. Lee,et al.  Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial , 2003, European journal of gastroenterology & hepatology.

[77]  U. Akarca,et al.  Interferon–Lamivudine Combination is No Better than Lamivudine Alone in Anti-Hbe-Positive Chronic Hepatitis B , 2003, Antiviral therapy.

[78]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[79]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[80]  A. Lok,et al.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. , 2002, Hepatology.

[81]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[82]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[83]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[84]  N McKoy,et al.  Systems to rate the strength of scientific evidence. , 2002, Evidence report/technology assessment.

[85]  D. Brenner,et al.  Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. , 2001, Journal of hepatology.

[86]  G. Barbarini,et al.  Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. , 2001, Journal of hepatology.

[87]  S. Ebrahim.  The Use of Numbers Needed to Treat Derived from Systematic Reviews and Meta-Analysis , 2001, Evaluation & the health professions.

[88]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[89]  C. Mulrow,et al.  Current methods of the US Preventive Services Task Force: a review of the process. , 2001, American journal of preventive medicine.

[90]  I. Olkin,et al.  Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement , 2000, Oncology Research and Treatment.

[91]  G Bréart,et al.  From the Cochrane Library , 2000, Revue d'epidemiologie et de sante publique.

[92]  G H Guyatt,et al.  Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. , 2000, JAMA.

[93]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[94]  G H Guyatt,et al.  Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. , 2000, JAMA.

[95]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[96]  P. Lee,et al.  Publication bias in meta-analysis: its causes and consequences. , 2000, Journal of clinical epidemiology.

[97]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[98]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[99]  W. Hop,et al.  Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment , 1999, Hepatology.

[100]  G. Yao,et al.  A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. , 1999, Chinese medical journal.

[101]  M. Buti,et al.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999, Hepatology.

[102]  D G Altman,et al.  Confidence intervals for the number needed to treat , 1998, BMJ.

[103]  H. Thomas,et al.  Quantitative hepatitis B virus DNA assessment by the limiting‐dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy , 1998, Journal of viral hepatitis.

[104]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[105]  R. D. de Man,et al.  Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. , 1998, Journal of hepatology.

[106]  A. Morabito,et al.  A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum , 1997, Hepatology.

[107]  V. Carreño,et al.  Efficacy of prolonged interferon‐alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy , 1997, Journal of viral hepatitis.

[108]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[109]  X. Causse,et al.  A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. , 1994, Journal of hepatology.

[110]  L. Bianchi,et al.  Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Swiss Association for the Study of the Liver. , 1994, Journal of hepatology.

[111]  J. Hoofnagle,et al.  A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. , 1993, The American journal of gastroenterology.

[112]  W. Stremmel,et al.  Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. , 1992, The European journal of medicine.

[113]  R. Hift,et al.  Safety and efficacy of interferon alpha-2b following prednisone withdrawal in the treatment of chronic viral hepatitis B. A case-controlled, randomised study. , 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[114]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[115]  I. Waked,et al.  Experience with interferon in chronic hepatitis B in Egypt. , 1990, Journal of chemotherapy.

[116]  E. Schiff,et al.  Interferon-prednisone therapy for hepatitis B , 1990, The Journal of the American Osteopathic Association.

[117]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[118]  J. Pillot,et al.  REACTIVATION OF HEPATITIS B , 1989, The Lancet.

[119]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[120]  J. Dienstag.  Benefits and Risks of Nucleoside Analog Therapy for Hepatitis , 2009 .

[121]  J. Reichen.  ACP Journal Club. Review: evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B. , 2009, Annals of internal medicine.

[122]  [EASL clinical practice guidelines. Management of chronic hepatitis B]. , 2009, Gastroenterologie clinique et biologique.

[123]  I. Gareen,et al.  NIH consensus development statement on management of hepatitis B. , 2008, NIH consensus and state-of-the-science statements.

[124]  J. You,et al.  Pharmacoeconomics of entecavir treatment for chronic hepatitis B. , 2008, Expert opinion on pharmacotherapy.

[125]  K. Demır,et al.  Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. , 2007, Acta gastro-enterologica Belgica.

[126]  M. Mohamadnejad.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2006, Archives of Iranian medicine.

[127]  T. Trikalinos,et al.  Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. , 2005, World journal of gastroenterology.

[128]  H. Lee,et al.  Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. , 2004, Journal of gastroenterology and hepatology.

[129]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[130]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[131]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[132]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[133]  R. Figueroa Barrios.  [Chronic hepatitis]. , 1995, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[134]  J. Sorda,et al.  A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up. , 1993, Gut.

[135]  R. Baumgarten,et al.  Low dose alpha interferon treatment in chronic hepatitis B virus infection. , 1993, Gut.

[136]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[137]  A. Makris,et al.  Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.

[138]  F. Villamil,et al.  Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. , 1990, Journal of hepatology.

[139]  R. Baumgarten,et al.  Treatment of chronic hepatitis B with interferon alfa-2b. , 1990, Journal of hepatology.

[140]  C D Naylor,et al.  Meta-analysis of controlled clinical trials. , 1989, The Journal of rheumatology.